COLUMBIA CARE LLC

View full entity profile (contributions, contracts, SEC) →

Lobbying Spend

—

Filings

Firms Hired

Active Period

2019–2023

Lobbying Spend by Year

Client-reported lobbying expenses on LDA filings

Year	Lobbying Spend	Filings	Firms
2023	—	1	1
2022	—	4	1
2021	—	5	1
2020	—	2	1
2019	—	4	1

Hired Firms

Lobbying firms retained by this client; amounts are client-reported expenses when available

Firm Name	Reported Spend	Filings
BROWNSTEIN HYATT FARBER SCHRECK, LLP	—	16

Government Bodies Lobbied

Government entities explicitly identified as targets in LDA filings

Government Body	Filings
HOUSE OF REPRESENTATIVES	13
SENATE	13
Executive Office of the President (EOP)	3
Health & Human Services, Dept of (HHS)	3
White House Office	3

Top Issues

Most frequently reported lobbying issues

Issue Code	Description	Reports
Medical/Disease Research/Clinical Labs	Medical/Disease Research/Clinical Labs	15

Bills Explicitly Cited (4)

Bill numbers found in source-reported LDA specific issue text; broad topic matches are excluded

S. 253117th Congress

Cannabidiol and Marihuana Research Expansion Act

2022 · fourth_quarter · Firm: BROWNSTEIN HYATT FARBER SCHRECK, LLP

Open original LDA filing ↗

Cited source text and reported amounts

Issues relating to cannabis research, including the DEA Aug. 12 2016 solicitation of applications to manufacture cannabis for research purposes (Docket No. DEA-447) S.253 - Cannabidiol and Marijuana Research Expansion Act HR: 5657 the Medical Marijuana Research act HR: 8454 Medical Marijuana and Cannabidiol Reseach Expansion Act

Client expense: — · Firm income: $20,000

Matched citations: S.253

S. 253117th Congress

Cannabidiol and Marihuana Research Expansion Act

2022 · third_quarter · Firm: BROWNSTEIN HYATT FARBER SCHRECK, LLP

Open original LDA filing ↗

Cited source text and reported amounts

Issues relating to cannabis research, including the DEA Aug. 12 2016 solicitation of applications to manufacture cannabis for research purposes (Docket No. DEA-447) S.253 - Cannabidiol and Marijuana Research Expansion Act HR: 5657 the Medical Marijuana Research act HR: 8454 Medical Marijuana and Cannabidiol Research Expansion Act

Client expense: — · Firm income: $20,000

Matched citations: S.253

H.R. 5657117th Congress

Medical Marijuana Research Act

2022 · second_quarter · Firm: BROWNSTEIN HYATT FARBER SCHRECK, LLP

Open original LDA filing ↗

Cited source text and reported amounts

Issues relating to cannabis research, including the DEA Aug. 12 2016 solicitation of applications to manufacture cannabis for research purposes (Docket No. DEA-447) S. 253 - Cannabidiol and Marihuana Research Expansion Act H.R. 5657 - Medical Marijuana Research Act

Client expense: — · Firm income: $20,000

Matched citations: H.R. 5657

S. 253117th Congress

Cannabidiol and Marihuana Research Expansion Act

2022 · second_quarter · Firm: BROWNSTEIN HYATT FARBER SCHRECK, LLP

Open original LDA filing ↗

Cited source text and reported amounts

Issues relating to cannabis research, including the DEA Aug. 12 2016 solicitation of applications to manufacture cannabis for research purposes (Docket No. DEA-447) S. 253 - Cannabidiol and Marihuana Research Expansion Act H.R. 5657 - Medical Marijuana Research Act

Client expense: — · Firm income: $20,000

Matched citations: S. 253

Source: Senate LDA

COLUMBIA CARE LLC — Lobbying Disclosure | Poliscope